Abstract: Cryopreserved stem cells with high cell viability after thawing were obtained by slow freezing using a DMSO-free cryopreservation medium. Stem cells and/or progenitor cells thereof are contacted with a DMSO-free cryopreservation medium, comprising between 4 v/v % and 25 v/v % of propylene glycol and between 1.0 w % and 10 w % of a sugar; and are subsequently subject to a slow-freezing process. Optionally, the cryopreservation medium may comprise serum albumin and/or hyaluronic acid.

Abstract: The present invention provides an intranasal method for delivery of intact mammalian cells to the brain for treatment of neurological deficits. This approach applies an intranasal instillation to directly administer cells to the brain, and is useful as therapy for patients with neurological deficit or those who may benefit from cellular therapy as a result of stroke, Alzheimer's, Parkinson's, diabetes, traumatic injury, surgery, cancer, or other diseases of the brain. This non-invasive method of delivering neuronal cells is desirable and safe.

Abstract: A method inducing chimerism and allograft tolerance by co-infusion of stem/progenitor-like cells and donor cells, wherein the donor cells can be bone marrow cells. The method also comprises the conditioning comprising depletion of CD4+ and CD8+ T-cells and administration of low doses of anti-neoplastic drugs. The inventive method comprises an aspect wherein allograft tolerance is induced without systemically suppressing the immune system.

Abstract: The present invention is directed to methods of diagnosing the presence or absence of a bacterial infection in a patient, in particular, a tuberculosis infection, by measuring exhaled, isotopically labeled nitrogen gas after administration of isotopically labeled isoniazid.

Abstract: The present disclosure relates to human facilitating cells (hFC), and methods of isolating, characterizing, and using such hFCs.

Abstract: The detection of rare cells can be achieved with high efficiency, without deteriorating the sensitivity of the detection. A detection method which enables the above-mentioned detection comprises: a first step of carrying out a pretreatment for removing erythrocytes from blood to prepare a cell suspension containing leukocytes and rare cells; a second step of providing all of the cells contained in the cell suspension produced in the first step onto an observation area having multiple holes formed thereon; a third step of taking an optical image of the cells that have been provided on the observation area; and a forth step of detecting the rare cells from the image obtained by the image taking in the third step.

Abstract: This invention relates to a sterilization agent for livestock bedding or a composting accelerator for organic waste or livestock bedding, comprising at least one Bacillus coagulans thermophilic bacterium or a combination of the at least one Bacillus coagulans thermophilic bacterium and at least one Bacillus subtilis mesophilic bacterium, as an active ingredient, wherein the Bacillus coagulans thermophilic bacterium as a preferable bacterium is viable at a temperature of 40 to 60° C. and the Bacillus subtilis mesophilic bacterium is viable at a temperature of 30 to 50° C., and the mesophilic bacterium also has a sterilizing effect on harmful bacteria in bedding; and to a method for sterilizing livestock bedding or a method for accelerating composting of organic waste or livestock bedding by using these agents each as an active ingredient.

Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).

Abstract: The disclosure describes fungal organisms and preparations useful for inhibiting infection by Xylella sp. and in the treatment of Pierce's Disease.

Abstract: A method for the simultaneous measurement of proteolylic enzyme generation and clot strength in plasma or whole blood or any appropriate biological sample derived from blood. The measurement method encompasses the use of a detectable substrate which includes a moiety that can be released upon reaction with the targeted proteolytic enzyme, and elements for measurement of an increase in viscosity of clot strength.

Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three tunes approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells/mL.

Abstract: The present invention relates to increase in survival of mammals suffering from desmocollin 3 expressing cancers. Mycobacterium w is administered to mammals suffering from desmocollin-3 expressing cancers. The administration of Mycobacterium w results in control of tumor and improvement in survival. Mycobacterium w can also be used along with other therapeutic agent(s)/modalities as per the requirement. The squamous type of non small cell lung cancer is known to be desmocollin-3 expressing cancer. Other cancers also express desmocollin-3.

Abstract: A method for the treatment of lignocellulose-containing materials wherein such lignocellulose-containing materials, normally resistant to biotreatment, are first subjected to pyrolysis to produce pyrolysis products including pyrogas and char. Exemplary applications of the method include pyrolytic pre-treatment of wastewater sludges, cellulosic wastes, wood, peat, plant residues, low-grade coal, and the like. The pyrogas is introduced into digester sludge in an anaerobic digester.

Abstract: A process for the use of peracid compositions to eliminate and/or control the growth of undesirable bacteria, including contaminating bacteria, in the fermentation production of alcohol is disclosed. Beneficially, the peracid compositions and methods of use of the same do not interfere or inhibit the growth or replication of yeast and have low or no adverse environmental impact.

Abstract: Presented is a kit containing TCPP for use in prognosing a patient's response to a cancer therapy wherein prior to the therapy contacting a sample of cells from the patient's tissue or organ being treated for the cancer with a solution of TCPP to permit binding of the TCPP to components of the abnormal dysplastic or carcinomic cells, if any are present; detecting TCPP fluorescence in the sample, the presence of TCPP fluorescence being indicative that the sample contains dysplastic or carcinomic cells; at intervals during the therapy and subsequent to the therapy performing steps a-c on another sample of cells from the patient's tissue or organ being treated for the cancer; and determining if the percentage of abnormal pre-cancerous cells in the samples tested during and subsequent to the therapy are reduced as compared with the sample tested prior to the therapy, the reduction being prognostic of the patients response to the cancer therapy.

Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof.

Abstract: The present novel technology relates to an autologous cell therapy that comprises a pre-determined amount of a processed bone marrow cellular matrix with a pre-determined amount of pre-mixture, where the pre-mixture includes quantities of anticoagulant solution, dextrose and phosphate buffered saline, and methods for production. The present novel technology further relates to a method of using the composition to reduce discogenic pain in humans.

Abstract: Methods and systems for processing and conditioning red blood cells are disclosed. The methods and systems may be used to make a readily transfusible red blood cell product with reduced plasma. In general, the plasma content of the supernatant of the red blood cell product is no greater than about 15%. The red blood cell products are prepared using the disclosed methods and systems remain transfusible for up to 42 days.

Abstract: A dry yeast composition which includes 5-adenosyl-L-methionine and a thickener and has excellent storage stability. A thickener is added to a yeast cell concentrate obtained by culturing yeast which has SAMe-producing ability and collecting the cells, and the resultant mixture is dried. Thus, a dry yeast containing a high concentration of 5-adenosyl-L-methionine which has excellent storage stability and excellent bioabsorbability can be easily and profitably produced. It is hence possible to supply a market with a dry yeast composition that contains a high concentration of 5-adenosyl-L-methionine, which is useful as a water-soluble physiologically active substance, and that has excellent storage stability and bioabsorbability.

Abstract: The present disclosure relates to pharmaceutical or nutritional compositions containing ?-galactosidase and ?-galactosidase and their use in the prevention and/or treatment of gastroesophageal reflux disease; in particular the present disclosure related to pharmaceutical or nutritional compositions.